Lisa A Carey
UNC Lineberger Comprehensive Cancer Center · University of North Carolina · University of North Carolina, Chapel Hill
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Lisa A Carey as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:26 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07340541 · Evolutionary Clinical Trial for Novel Biomarker-Driven TherapiesUNC Lineberger Comprehensive Cancer Center · recruiting · Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer · principal investigator
- Ph3NCT05207709 · Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic SubtypeSOLTI Breast Cancer Research Group · terminated · Metastatic Breast Cancer · principal investigator
- N/ANCT03769415 · Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCAUNC Lineberger Comprehensive Cancer Center · recruiting · Breast Cancer · principal investigator
- N/ANCT03161821 · Circulating Tumor Cells in Solid TumorsUNC Lineberger Comprehensive Cancer Center · completed · Solid Tumor, Adult · principal investigator
- Early Ph1NCT01875666 · Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + LapatinibUNC Lineberger Comprehensive Cancer Center · completed · Breast Neoplasms · principal investigator
- N/ANCT01000883 · Correlation of Molecular Markers With Response to Therapy and Breast Cancer BehaviorUNC Lineberger Comprehensive Cancer Center · recruiting · Breast Cancer · principal investigator
- Ph3NCT00770809 · Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by SurgeryNational Cancer Institute (NCI) · completed · Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7 · principal investigator
- Ph2NCT00764322 · Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving TamoxifenUNC Lineberger Comprehensive Cancer Center · completed · Breast Cancer, Menopausal Symptoms · principal investigator
- Ph2NCT00232505 · Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast CancerUNC Lineberger Comprehensive Cancer Center · completed · Breast Cancer · principal investigator
- Ph2NCT00006110 · Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast CancerUNC Lineberger Comprehensive Cancer Center · completed · Breast Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Career Enhancement ProgramP50CA058223 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · fiscal years 2006 to 2026 · $76,110 awarded in 2026Grant number is on one of their registry trials
- Elucidating the molecular mechanisms of metastasis organ tropismU01CA289839 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · fiscal years 2025 to 2026 · $639,718 awarded in 2026Same name and institution; not confirmed by an ID
- Optimizing prognostic and predictive algorithms using residual disease (RD) genomic biomarkers in HER2+ and TNBCR01CA229409 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · fiscal years 2019 to 2026 · $590,870 awarded in 2026Same name and institution; not confirmed by an ID
- UNC Lead Academic Participating SiteUG1CA233373 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · fiscal years 2019 to 2025 · $454,679 awarded in 2025Same name and institution; not confirmed by an ID
- Breast Cancer Research ProgramP30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · fiscal years 2011 to 2024 · $42,152 awarded in 2024Grant number is on one of their registry trials
- NCTN Lead Academic Participating Sites ApplicationU10CA180838 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · fiscal years 2014 to 2018 · $623,046 awarded in 2018Same name and institution; not confirmed by an ID
- Academic Training in Oncology at the University of North Carolina at Chapel HillT32CA128590 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · fiscal years 2011 to 2012 · $255,067 awarded in 2012Same name and institution; not confirmed by an ID
- LCCC 0403: PHASE II CETUXIMAB ALONE AND IN COMBINATION WITH CARBOPLATINM01RR000046 · NCRR · UNIV OF NORTH CAROLINA CHAPEL HILL · fiscal years 2004 to 2007 · $750 awarded in 2007Grant number is on one of their registry trials
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026Named on NCT00770809
- Cancer and Leukemia Group BU10CA031946 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Monica M Bertagnolli · fiscal years 1985 to 2013Named on NCT00770809
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:26 UTC. The ranking covers the 200 most relevant of 81 PubMed records, and a shared surname and initials can bring in a namesake. All 81 on PubMed
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.N Engl J Med · 20211,463 citationsRCR 83.1
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.N Engl J Med · 20201,043 citationsRCR 46.1
- 782 citationsRCR 22.7
- Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.N Engl J Med · 2015582 citationsRCR 16.4
- Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.Clin Cancer Res · 2013569 citationsRCR 15.6
- TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.J Clin Oncol · 2012419 citationsRCR 10.3
- TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.J Clin Oncol · 2020417 citationsRCR 15.8
- Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.J Clin Oncol · 2008370 citationsRCR 8.2
- 345 citationsRCR 10.2
- TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.J Clin Oncol · 2015335 citationsRCR 9.5